"An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol" by Hua Ling

Article

An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol

Cardiovascular Therapeutics (2014)

Hua Ling, Creighton University
Tammy L. Burns, Creighton University
Daniel E. Hilleman, Creighton University

Link

Disciplines

Pharmacology,
Cardiology,
Internal Medicine,
Medicine and Health Sciences and
Endocrinology

Publication Date

April 1, 2014

DOI

10.1111/1755-5922.12056

Citation Information

Hua Ling, Tammy L. Burns and Daniel E. Hilleman. "An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol" Cardiovascular Therapeutics Vol. 32 Iss. 2 (2014) p. 82 - 88
Available at: http://works.bepress.com/hua-ling/17/